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Peritoneovenous shunt in the management of the hepatorenal syn-
drome. The hepatorenal syndrome (HRS) is a terminal complication of
severe liver disease associated with a mortality of 80 to 90%. Although
the renal functional abnormalities in the HRS suggest prerenal
azotemia, volume expansion with saline, albumin or ascitic fluid rarely
results in reversal of the HRS because fluid redistributes from the
vascular space. Since the peritoneovenous (PV) shunt causes sustained
central volume expansion, it has been advocated for the treatment of
the HRS. We prospectively compared the PV shunt (N = 10) to
Medical Therapy (MED) (N 10) on renal function and mortality in 20
patients with the HRS associated with alcoholic liver disease. The HRS
was diagnosed on the basis of clinical, hemodynamic, and laboratory
criteria. The insertion of a PY shunt resulted in an increase in
pulmonary capillary wedge pressure (4.2 1.1 vs. —1.5 1.0mm Hg,
P < 0.01) and in cardiac index (0.8 0.3 vs. —0.2 0.3 1/minIm2, P <
0.05). After 48 to 72 hours, weight (+ 3.1 1.1 kg) and serum creatinine
(3.9 0.5 to 5.5 0.7 mg/dl, P C 0.001) were increased with MED
therapy and decreased (weight: —3.7 0.7 kg; serum creatinine: 3.6
0.4 to 3,0 0.5, P C 0.05) with the PV shunt. Despite improvement in
renal function, only one patient with the PV shunt had prolonged
survival (210 days). In the remainder, survival was 13.8 2.2 days
compared to 4.1 0.6 days with MED therapy. We conclude that the
PV shunt often stabilizes renal function, but does not prolong life in
patients with the HRS.
The hepatorenal syndrome (HRS) is defined as functional
renal failure complicating the course of hepatic cirrhosis. It
occurs in the absence of clinical or laboratory evidence of other
known causes of renal failure and is invariably progressive in
nature. The HRS is associated with a mortality of greater than
80 to 90% [1, 21.
The pathophysiologic abnormalities responsible for renal
failure in the HRS are incompletely understood [1, 2]. The lack
of consistent histopathological lesions [31, the improvement in
renal function occurring with normalization of the hepatic
environment [4], the unremarkable urinalysis and the low
urinary sodium excretion, all suggest a functional renal hemo-
dynamic defect. In this regard, the renal cortical vasoconstric-
tion, increased renal vascular resistance [5, 61, enhanced renal
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renin secretion [7, 8], and avid renal tubular sodium and water
reabsorption in the HRS are similar to the renal physiological
response to hypoperfusion further supporting a hemodynamic
deficit. The suggestion that renal hypoperfusion may be impor-
tant in the pathogenesis of the HRS has led investigators to
increase intravascular volume by infusion of saline, albumin or
ascitic fluid [9—111. At best, these efforts result in transient
improvement in renal function. More recently, an improved
method to chronically expand extracellular fluid volume by
shunting ascitic fluid to the venous circulation has been used
with increasing frequency. The development by LeVeen et al
[12] of an improved peritoneovenous (PV) shunt with a pressure
activated one—way valve has been responsible for this resur-
gence of interest. The PV shunt has been used successfully to
increase renal sodium and water excretion in patients with
ascites refractory to medical management [13—15]. Based on
these favorable results, the PV shunt has also been advocated
as a therapeutic maneuver in the HRS [16—17]. Several case
reports and uncontrolled trials suggest great benefit [13, 18—21].
However, in these studies, the diagnosis of the HRS was not
always proven; rather, some of these patients may have had
reversible azotemia secondary to intravascular volume contrac-
tion [15, 221. Moreover, the PV shunt may be associated with
substantial complications including mechanical failure, infec-
tion, volume overload, and disseminated intravascular coagu-
lation [221. Therefore, the purpose of the present study was to
determine the clinical efficacy of the PV shunt in a prospective
study of patients with well—defined HRS.
Methods
Patient selection
Patients with alcohol—related liver disease, ascites, and pro-
gressive renal insufficiency compatible with the HRS were
recruited from the medical services of Denver General Hospital
and the University Hospital. Alcohol—related liver disease was
diagnosed on the basis of liver biopsy (N = 4) or all of the
following criteria: 1) history of heavy (>150 glday) and pro-
longed (>5 years) alcohol ingestion or multiple alcohol
detoxification admissions; 2) an enlarged firm liver and charac-
teristically abnormal biochemical tests including increased
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Table 1. Clinical characteristics of patients with the
hepatorenal syndrome
PV Shunt Medical
Men/Women 7/3 7/3
Age 48.1 3.6 47.8 4.6
(years) (36—64) (32—61)
Prior history
Encephalopathy 4/10 3/10
Variceal bleeding 3/10 5/10
Spontaneous peritonitis 2/10 1/10
Ascites 10/10 10/10
Peripheral edema 10/10 10/10
Number of days in 14.1 4.4 12.5 2.7
hospital prior to entry
into study
Weight gain during 5.62 1.0 8.22 1.8
hospitalization prior to
entry into study (kg)
bilirubin, alkaline phosphatase and SGOT; and 3) absence of
evidence of other causes of liver disease.
Patients were considered to have functional renal failure
compatible with the HRS on the basis of all of the following
criteria: 1) no history of underlying renal disease; 2) no history
of toxin exposure; 3) urine sediment without cellular casts; 4)
no significant proteinuria (qualitative tests:  1+, 24 hr urine
protein <1 g); 5) no clinical evidence of obstruction (normal
prostatic or pelvic exam, nonobstructive renal ultrasound, or
when clinically indicated, no significant residual urine on
straight catheterization); 6) urinary sodium concentration 20
mEqlliter, urine volume <500 ml/day, renal failure index <1;
and 7) serum creatinine l.8 mg/dl which had risen on three
consecutive determinations over six days and was at least 0.5
mgldl increased over baseline despite volume expansion. Prior
to entering the study, each patient had gained substantial
weight. Moreover, to exclude prerenal azotemia, each patient
had received either two liters of normal saline or two liters of
normal saline containing 25 g albumin/liter in addition to main-
tenance fluid in the 48 hours prior to entering the study. Patients
were excluded from the study if they had kidney or liver
diseases which were incompatible with the HRS, a recent
episode of spontaneous bacterial peritonitis (<3 months), car-
diac disease which would preclude the insertion of a PV shunt
or clinically significant bleeding.
Study design
Twenty patients were entered into the study. A Swan—Ganz
catheter was placed by an experienced investigator for the
determination of hemodynamic parameters. Hemodynamic
pressures were measured on a transducer system by means of a
Statham P23Db transducer (Statham Instruments, Heta Rey,
Puerto Rico) with zero reference at midchest and a Hewlett—
Packard recording system (Hewlett—Packard, Elkhart, Indiana,
USA). Pressure measurements were obtained with the patient
in the supine position and at end expiration. Cardiac output was
determined by the thermodilution technique, and the mean of
three determinations was recorded. Systemic vascular resist-
ance (SVR) was calculated from the formula: SVR = [mean
arterial pressure minus right atrial pressurel x 80 divided by the
cardiac output. The mean arterial pressure (MAP) was esti-
Table 2. Selected parameters of liver function in patients with
hepatorenal syndromea
Study entry
TB AP SGOT Alb PT
PV shunt 22.2 325 146 2.47 14.7
(10) 4.4 49 19 0.6
Medical 23 354 188 2.45 16.1
(10) 2.6 36 22 0.8
P NS NS NS NS NS
a Abbreviations are: TB, total bilirubin (mgldl); AP, alkaline phos-
phatase (units); SGOT, serum glutamic—oxaloacetic transaminase
(units); Alb, albumin (g/dl); and PT, prothrombin time (seconds).
Table 3. Selected parameters of renal function in patients with the
hepatorenal syndromea
Initial Study entry
BUN Creatinine UNa BUN Creatinine UNa
PV Shunt 16.2 1.34 10.8 63.4 3.64 9.6
(10) 4.5 .16 1.4 .38 1.7
Medical 16.8 1.32 7.1 43.3 3.94 10.1
(10) 3.6 .23 1.3 7.0 .52 1.6
P NS NS NS NS NS NS
a Data are presented at the time of hospitalization and at entry to the
study. Abbreviations are: BUN, blood urea nitrogen (mg/dl); Creati-
nine, serum creatinine (mg/dl); and UNa, urinary sodium concentration
(mEq/liter).
mated by the equation: MAP = diastolic pressure + [(systolic
pressure minus diastolic pressure) 3]. Patients were then
randomized by random number technique to receive either
standard medical therapy or a PV shunt. Nine patients received
a LeVeen shunt and one patient, a Denver shunt. The PV shunt
was placed within 24 hours of randomization by a surgeon
experienced in its placement. The medically treated group was
managed in the standard manner for our hospital. This included
the judicious administration of combinations of volume (saline
colloid) and pressors (dopamine and norepinephrine). Hemo-
dynamic parameters were reassessed after 48 hours in medi-
cally treated patients and 18 to 24 hours after surgery (42 to 48
hours after randomization) in patients receiving the PV shunt.
In the PV shunt group attempts were made to maintain urine
volume >50 mllhour after surgery. No patient accomplished
this within the first 12 hours after surgery. All patients then
received furosemide (40 to 160 mg/day) to maintain urine
volume.
Laboratory tests. Urine and blood tests were performed by
the clinical laboratory utilizing standard methodology.
Statistical techniques
Statistics were performed with a two—tailed unpaired t-test
for single comparisons and analysis of variance for multiple
comparisons. Results are expressed as the mean SEM.
Study approval
The study was approved by the Independent Review Com-
mittee of Denver General Hospital. Informed consent was
obtained from each patient or from a responsible family mem-
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Table 4. Hemodynamic parameters in patients with the hepatorenal syndrome
ber when a patient was not considered competent to provide
consent.
Results
Table 1 lists the characteristics of the patient population. The
groups were comparably matched with respect to age, sex and
complications of liver disease. Since the HRS is a complication
of severe liver disease, there was a high incidence of encepha-
lopathy and variceal bleeding.
Table 2 demonstrates selected parameters of liver function at
the time of randomization. At the time of entry to the study,
there were no differences in serum concentration of albumin,
SGOT, alkaline phosphatase, total bilirubin, or prothrombin
time in patients to receive the PY shunt compared to patients to
receive medical therapy. Each patient had severe liver disease
as manifested by abnormalities in each test of liver function. In
addition, serum levels of bilirubin and albumin had become
progressively more abnormal during hospitalization.
Selected parameters of renal function at the time of hospital-
ization and at entry into the study are shown in Table 3. There
were no differences between the groups in blood urea nitrogen
(BUN), creatinine, or urinary sodium concentration at either
time. Both groups had intense renal sodium conservation.
During the course of hospitalization, there was a profound
decrease in renal function in both groups. This was manifested
by an increase in BUN and serum creatinine in all patients. The
deterioration in serum creatinine occurred despite volume
administration and substantial weight gain (Table 1).
Table 4 demonstrates systemic hemodynamics at the time of
randomization and after the PV shunt or medical therapy. At
the time of randomization both groups were comparable. When
compared to normal patients in our hospital, patients with the
HRS had a decrease in SVR and an increase in cardiac index
(CI). Because of the nature of the entry criterion for the study
(that is, all patients had received repeated volume challenges),
pulmonary capillary wedge pressure (PCWP) was normal in
each patient. In the medically treated group, there were small
decreases in each hemodynamic parameter over the ensuing 48
hours despite the use of pressor agents. In contrast, there were
small increnses in both PCWP and CI in patients treated with
the PV shunt.
Figure 1 demonstrates the effect of the PV shunt versus
medical therapy on serum creatinine. Data were presented at 72
hours after randomization in 18 patients, and at 48 hours in two
patients in the medical group who died prior to 72 hours. In the
medically treated group, each patient had a further increase in
0 I
Entry 72 hours Entry 72 hours
Fig. 1. The effect o,fmedical therapy or the peritoneovenous shunt on
serum creatinine in patients with the hepatorenal syndrome. Data is
presented at entry into the study and after 72 hours, except for two
patients in the medically treated group where data is presented at 48
hours.
serum creatinine despite an increase in weight (3.08 1.1 kg).
In contrast, serum BUN (—2.4 6.3 vs. 23.3 6 mgldl, P <
0.01) and creatinine stabilized or improved in eight of ten
patients who received the PV shunt. Since the patients in the
PV shunt group had received furosemide, the improvement in
renal function was associated with significant weight loss
(—3.67 0.7 kg) and an increase in urinary sodium concentra-
tion (29.3 2.2 mEq/liter).
Figure 2 demonstrates the effect of the PV shunt compared to
medical therapy on patient mortality. All 20 patients died during
the course of the study. In the medically treated group, mor-
tality occurred within two to seven days of randomization. In
the surgically treated group, one patient died after 210 days.
When this individual was excluded from statistical analysis,
mean survival was 13.8 2.2 days with a range of five to 23
days.
Adverse reactions were similar in both groups of patients. In
the medically treated group, two patients had gastrointestinal
bleeding and one patient developed sepsis from an unknown
source. In the PV shunted group, every patient had a decrease
in platelet count (mean decrease of 35 8% basal) and an
increase in prothrombin time (2.2 0.8 sec). In addition one
patient had shunt malfunction, abdominal infection and sepsis.
Two patients had persistent gastrointestinal bleeding requiring
shunt ligation.
Entry
MAP PCWP CI SVR
Changes in hemodynamics with therapy
PY shunt
(10)
Medical
(10)
P
81
2.0
84
4.0
NS
MAP
—2.0
—2.0
NS
PCWP CI SYR
+4.2
÷1.1
—1.5
<0.01
+0.8
—0.2
<0.05
—151
62
35
71
NS
11.5
0.8
11.0
1.0
NS
4.2
5.0
NS
829
89
745
76
NS
a Data are presented at the time of entry into the study and 48 hrs after medical or surgical therapy. Abbreviations are: MAP, mean arterial
pressure (mm Hg); PCWP, pulmonary capillary wedge pressure (mm Hg); CI, cardiac index (liter/minim2); and SVR, systemic vascular resistance
(dynes/sec-cm5).
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Fig. 2. Number of days between entry into the study and death in
patients with the hepatorenal syndrome treated medically or with the
PV shunt. Numbers in boxes refer to number of patients dying on a
given day.
Discussion
To be considered as having a diagnosis consistent with the
HRS, each patient had a rising serum creatinine and intense
renal sodium conservation. Although these laboratory parame-
ters occur in the HRS, prerenal azotemia caused by either a
decrease in intravascular volume or by left ventricular dysfunc-
tion also can occur in patients with severe liver disease and can
mimic the laboratory findings of the HRS [23]. For example, in
preliminary studies we found that as many as 25% of patients
with suspected HRS had prerenal azotemia as manifest by a
decrease in PCWP or an increase in PCWP with left ventricular
dysfunction. Therefore, in the current study we administered
volume and measured central hemodynamics to exclude diag-
nosis other than the HRS. Although the volume of saline (or
saline plus albumin) was arbitrarily chosen to be 2 liters, no
patient had hemodynamic characteristics of either hypovolemia
(decreased PCWP) or of left ventricular dysfunction (decreased
cardiac index despite adequate filling pressure). Thus, by the
use of clinical, laboratory and hemodynamic citeria we were
able to identify a uniform group of patients with functional renal
failure in the absence of reversible prerenal causes.
The rationale for the PV shunt is based on the observation
that liver function eventually improves in patients with alco-
holic liver disease after abstaining from alcohol. However, this
may take months and some patients die of kidney failure. Since
the renal functional abnormalities resemble those found in
hypoperfusion states, attempts have been made to reverse renal
dysfunction by intravascular volume expansion with saline,
albumin or ascitic fluid [9—111. While volume expansion occa-
sionally improves glomerular filtration rate, this effect is often
transient because fluid is rapidly redistributed from the vascular
to the extravascular compartment. This has led to the postulate
that sustained expansion of the vascular compartment might
reverse the decrease in effective plasma volume which occurs in
the HRS. To test this hypothesis, we determined the effect of
the PV shunt on central hemodynamics. Compared to patients
receiving medical therapy in whom central filling pressures fell
and serum creatinine increased, the insertion of a PV shunt
resulted in a small increase in central filling pressures as
manifested by an increase in PCWP and in cardiac index (Table
4). In association with the beneficial effects of the PV shunt on
central hemodynamics, eight of 10 patients had stabilization or
improvement in renal function. This data suggests that renal
dysfunction in this group of patients was related to arterial
vasodilation and subsequent arterial hypovolemia. In contrast
to these eight patients, renal function continued to deteriorate
in two patients despite comparable increases in central hemo-
dynamics. Although we cannot exclude the possibility of arte-
rial volume depletion, it is possible that the pathogenesis of
renal failure in these two individuals was mediated by abnor-
malities in renal hemodynamics which had been activated by
factors other than arterial volume depletion. Alternatively,
these patients may have had acute tubular necrosis. Since the
number of patients is small, further studies will be necessary to
determine the mechanism of the beneficial effects of the PV
shunt and furosemide on renal function in the HRS.
In contrast to other reports [13, 18—21], we did not find
improved survival with the PV shunt in HRS. Of the 10 patients
receiving a PV shunt, only one survived hospitalization. Pa-
tients in the PV group survived 13.8 2.2 days (excluding one
prolonged survivor) compared to 4.1 0.6 days in the medical
group.
There are several possible explanations to account for the
observation that life expectancy was only marginally improved
in the PV group despite the beneficial group on systemic
hemodynamics and renal function. One possibility is that the
effect of the PV shunt on hemodynamics and renal function
differed at 72 hours and at the time of death. This seems
unlikely since renal function remained stable in the PV group
and only deteriorated over the 24 hours prior to death. An
additional possibility could be the design of our study. Our goal
was to obtain a uniform patient population with the HRS rather
than with prerenal azotemia. In this regard, patients had been
hospitalized for a mean of 12 to 14 days prior to meeting entry
criterion for the study. Moreover, the level of bilirubin (that is,
greater than 20 mg/dl) has been associated with acute tubular
necrosis in the setting of obstructive liver disease [24]. It is
possible, therefore, that by intervening in the course of hospi-
talization or in patients with less jaundice, we would have
observed a beneficial effect on mortality. We believe, however,
that the marginal effect of the PV shunt was not related to the
study design, but to the nature of the HRS. Renal failure is not
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the primary abnormality in the HRS, but rather a terminal
complication of severe liver disease. For example, it has been
shown that liver transplantation in patients with MRS results in
rapid improvement in renal function [41. Moreover, transplan-
tation of kidneys from patients with HRS into recipients with
normal livers also reverses renal disease [25]. It seems likely,
therefore, that the marginal improvement in life expectancy in
our patients with HRS was related to the progressive nature of
the severe liver disease, rather than to problems of study
design.
While others have reported a high incidence of complications
after insertion of the PV shunt [22], our experience suggests
that adverse reactions in patients with a PV shunt were not
necessarily related to the PV shunt but, rather, to the severe
nature of the HRS as there were the same percentage of severe
complications (30%) in both the PV shunt and medically treated
groups.
In summary, the HRS is associated with high morbidity and
mortality. Compared to patients treated medically, the insertion
of a PV shunt and the administration of furosemide resulted in
an improvement in systemic hemodynamics and renal function.
Despite this improvement in renal function, there was only a
marginal improvement in life expectancy in the PV shunted
group. We conclude that the insertion of a PV shunt should not
be utilized as standard therapy for the treatment of patients with
the HRS. This does not exclude the possibility, however, that
the insertion of a PV shunt may be beneficial in selected
patients in whom progressive functional renal failure occurs in
the setting of mild jaundice or in patients in whom functional
renal failure occurs at a time when liver function is improving.
Acknowledgments
Ms. Carolyn Bignall provided secretarial assistance for this manu-
script. We acknowledge the medical housestaff of the University of
Colorado School of Medicine, the nursing staff of Denver General
Hospital, and Dr. Patricia Gabow for their unfailing support of this
project.
Reprint requests to Stuart L. Linas, MD., Department of Medicine,
Box 4000, Denver General Hospital, Denver, Colorado 80204-4507,
USA.
References
1. PAPPER 5: Hepatorenal syndrome, in The Kidney in Liver Disease
New York, edited by M EPSTEIN. Elsevier Science Publishing Co.,
pp. 86—106, 1983
2. EPSTEIN M: Hepatorenal syndrome, in Bockus, Gastroenterology
(4th ed), edited by JE BERK. Philadelphia, WB Saunders Co., pp.
3138—3149, 1985
3. VAAMONDE CA, PAPPER 5: The Kidncy in Liver Disease, in
Diseases of the Kidney (3rdcd), cdited by STRAuss, WELT. Boston,
Little, Brown and Company, pp. 1289—1317, 1979
4. IwATsuKI 5, POPOvTZER MM, CORMAN JL, ISHIKAwA M,
PUTNAM CW, KATZ FM, STARZL TE: Recovery from "hepatorenal
syndrome" after orthotopic liver transplantation. N Engi I Med
289:1155—1159, 1973
5. EPSTEIN M, BERK DP, HOLLENBERG NK, ADAMS DF, CHALMERS
TC, AIIRAMS ML, MERRILL JP: Renal failure in the patient with
cirrhosis. The role of active vasoconstriction. Am I Med 49:
175—185, 1970
6. BALDUS WP, SUMMERSKIL WHJ, HUNT JC, MAHER FT: Renal
circulation in cirrhosis: Observation based on catheterization of the
renat vein. I Clin Invest 43:1090—1097, 1964
7. SCHROEDER ET, EICM RH, SMULYAN H, GOULD AB, GAIIUZDA
GJ: Plasma renin level in hepatic cirrhosis: Relation to functional
renal failure. Am J Med 49:186—19t, 1970
8. WoNo PY, TALAMO R, WILLIAMS GM: Kallikrein—kinin and
renin—angiotensin systems in functional renal failure of cirrhosis of
the liver. Gastroenterology 73:1114—I 118, 1977
9. REyNOLDs TB, LIERERMAN FL, REDEKER AG: Functional renal
failure with cirrhosis. The effect of plasma expansion therapy.
Medicine 46:191—196, 1967
10. CLERMONT RJ, VLAHcEvIc ZR, CHALMERS TC, ADHAM NF,
CURTIS GW, MORRISON RS: Intravenous therapy of massive
ascites in patients with cirrhosis. Gastroenterology 53:211,
220—228, 1967
11. EICNOvAN G, MARTINEZ—MALDONADO M, YUIM JJ, SUn WN:
Combined ascitic fluid infusion and furosemide in the management
of ascites. N Engi I Med 282:713—717, 1970
12. LEVEEN MM, CHRISTOUDIA5 G, II' M, LUFT R, FALK G,
GROSBERO 5: PeritoneovenouS shunting for ascites. Ann Surg
180:580—590, 1974
13. SCHROEDER ET, ANDERSON GH, SMULvAN H: Effects of a porta-
caval or peritoneovenous shunt on renin in the hepatorenal syn-
drome. Kidney Int 15:54—6!, 1979
14. BLENDIS LM, GREIG PD, LANGER B, BAIGRIE RS, RUSE J, TAYLOR
BR: The renal and hemodynamic effects of the peritoneovenous
shunt for intractable ascites. Gastroenterology 77:250—257, 1979
15. EPSTEIN M: The LeVeen shunt for ascites and the hepatorenal
syndrome. N Engi I Med 302:628—630, 1980
16. LEVEEN MM, BROWN T, D'OvlDIo NG: Surgical treatment of
aScites. Adv Surg 14:107—149, 1980
17. KINNEYMJ, SCHNEIDER A, WAPNICK 5, GRO5BERG 5, LEVEEN H:
The 'hepatorenal syndrome' and refractory ascites: Successful
therapy with the LeVeen—type peritoneal—venous shunt and valve.
Nephron 23:228—232, 1979
18. PLADSON TR, PARRISH RM: Mepatorenal syndrome: Recovery
after peritoneovenous shunt. Arch Intern Med 137:1248-1249, 1977
19. GROSBERG SJ, WAPNICK 5: A retrospective comparison of func-
tional renal failure in cirrhosis treated by conventional therapy or
the peritoneovenous shunt (LeVeen). Am I Med Sci 276:287—291,
1978
20. SCHWARTZ ML, VOGEL SB: Treatment of hepatorenal syndrome.
Am I Surg 139:370—373, 1980
21. FULLEN WD: Hepatorenal syndrome: Reversal by peritoneoven-
ous shunt. Surgery 82:337—341, 1977
22. EPSTEIN M: The peritoneovenous shunt in the management of
ascites and the hepatorenal syndrome. Gastroenterology 82:790—
799, 1982
23. TRI5TANI FE, COHN JN: Systemic and renal hemodynamics in
oliguric hepatic failure: Effect of volume expansion. I Clin Invest
46: 1894-1906, 1967
24. DAwsoN JL: Post-operative renal function in obstructive jaundice:
Effect of a mannitol diuresis. Br Med 1 1:82—86, 1965
25. KOPPEL MM, COBURN JW, MIMS MM, GOLDSTEIN M, BOYLE JD,
RUBINI ME: Transplantation of cadaveric kidneys from patients
with hepatorenal syndrome. Evidence for the functional nature of
renal failure in advanced liver disease. N Eng! I Med 280:
1367—1371, 1969
